Australia markets closed

PYC Therapeutics Limited (PYC.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.1100+0.0160 (+17.02%)
At close: 04:10PM AEDT
Full screen
Previous close0.0940
Open0.1000
Bid0.1000 x 42340100
Ask0.1100 x 21464600
Day's range0.0930 - 0.1100
52-week range0.0500 - 0.1100
Volume10,496,918
Avg. volume1,701,784
Market cap410.616M
Beta (5Y monthly)0.26
PE ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings date26 Feb 2024 - 01 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.30
  • PR Newswire

    PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE

    PYC Therapeutics today announces the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication[8].

  • Simply Wall St.

    Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

  • PR Newswire

    US FDA DESIGNATES PYC'S LEAD AS A FAST TRACK DEVELOPMENT PROGRAM

    PYC Therapeutics Limited (ASX:PYC) today announces that the VP-001 program, the first investigational drug candidate designed to address Retinitis Pigmentosa type 11 (RP11) to progress to human trials, has received Fast Track designation from the US Food and Drug Administration (FDA).